The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
06/22/2009
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Description of Modification
The purpose of this modification is to add the full announcement and Appendices A&B.
Document Type:
Modification to Previous
Grants Notice
Funding Opportunity Number:
DARPA-BAA-09-43
Opportunity Category:
Discretionary
Posted Date:
Jun 22, 2009
Creation Date:
Jun 23, 2009
Original Closing Date for Applications:
Jun 21, 2010
Current Closing Date for Applications:
Jun 21, 2010
Archive Date:
Jul 21, 2010
Funding Instrument Type:
Cooperative Agreement
Grant
Other
Procurement Contract
Category of Funding Activity:
Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
Award Ceiling:
Award Floor:
CFDA Number(s):
12.910
--
Research and Technology Development
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Agency Name
DARPA - Defense Sciences Office
Description
DARPA is soliciting innovative medical therapeutic research proposals in two areas: Soldier Protection and Biodefense. Proposed research should investigate innovative approaches and revolutionary advances in science, devices, and/or systems. Specifically excluded are evolutionary or incremental improvements to existing practices.In recent years global surveillance networks have determined that the frequency and diversity with which new infectious microorganisms are emerging is increasing. While these increases are in part due to better reporting, there are multiple examples demonstrating this increase is promulgated by changes in natural systems, and potentially the activities of humans. Examples of factors implicated in the increase in new, emerging and re-emerging pathogens include: increased animal-human interface; increased population densities and co-location of vulnerable species with pathogen reservoirs; climate change, particularly affecting migration and spread of vectors; and narrowing of genetic diversity among food animal stocks. The expansion of biomedical technologies on the global stage is also suspected to increase the risk of orthogonal and highly diverse microorganisms. One growing concern is the potential risk posed by the proliferation of genetic engineering technologies that can be easily redirected from beneficent to offensive purposes or for covert biological industrial sabotage of food animals. Together, these natural occurring and synthetic threat agents challenge current detection methods and could possibly defeat traditional medical countermeasures. No group is at greater risk of exposure to new international pathogens, to bio-sabotage of food supply lines, or of attack from biological threat agents, then the U. S. Military. The traditional medical response for responding to large scale infectious disease outbreaks is to 1) quarantine exposed personnel (hours to weeks); 2) identify and characterize the agent (usually within 0-90 days); 3) develop a vaccine or therapeutic (1-14 years); and 4) to stockpile, distribute, and administer treatment. In cases where the pathogen is unknown or difficult to characterize, victims are likely to succumb before an effective therapy or vaccine can be developed, distributed and administered. DARPA/DSO is soliciting research proposals that seek to develop highly innovative approaches to counter any known, unknown, naturally occurring or engineered pathogen. Proposed research will investigate novel technologies to prevent infection, extend survival until a curative response is available, provide transient immunity, or speed the onset of adaptive immunity. Methods proposed should not require prior knowledge of the pathogen and should be broadly applicable to multiple unrelated infectious agents.7-Day Biodefense is a two phase program focused on four Technical Areas: 1) Prevent Infection; 2) Sustain Survival; 3) Provide Transient Immunity; and 4) Create Persistent Immunity. Each proposal must respond to only one of these technical areas and provide an aggressive research schedule with milestones that demonstrate a clear path to achieving the end of phase metric. There will be a Live Fire Test in Areas Three (Provide Transient Immunity) and Four (Create Persistent Immunity) to demonstrate capability against a DARPA-designated unknown biological agent in an animal model (details provided in these technical area descriptions).Novel approaches that obviate traditional and rate-limiting steps are of particular interest (e.g. pathogen isolation, culture, identification, antigen processing by the immune system, and onset of adaptive immunity). This BAA is seeking pre-clinical validation only. Human clinical trials are specifically excluded. Also excluded from consideration is research that results in incremental and evolutionary improvements to the existing state of practice (e.g. ventilator/mask technologies, use of traditional post-exposure antibiotics).
Link to Full Announcement
If you have difficulty accessing the full announcement
electronically, please contact:
The following files represent the modifications to this synopsis
with the changes noted within the documents. The list of files is
arranged from newest to oldest with the newest file representing the
current synopsis. Changed sections from the previous document are shown
in a light grey background.
